Publicacións en colaboración con investigadores/as de Hospital Universitario La Paz (18)

2022

  1. Comparison of pneumonia features in children caused by SARS-CoV-2 and other viral respiratory pathogens

    Pediatric Pulmonology, Vol. 57, Núm. 10, pp. 2374-2382

  2. Viruses and Mycoplasma pneumoniae are the main etiological agents of community-acquired pneumonia in hospitalized pediatric patients in Spain

    Pediatric pulmonology, Vol. 57, Núm. 1, pp. 253-263

2021

  1. Diagnostic Accuracy of the Panbio Severe Acute Respiratory Syndrome Coronavirus 2 Antigen Rapid Test Compared with Reverse-Transcriptase Polymerase Chain Reaction Testing of Nasopharyngeal Samples in the Pediatric Population

    Journal of Pediatrics, Vol. 232, pp. 287-289.e4

  2. Interferon-Gamma Release Assays Differentiate between Mycobacterium avium Complex and Tuberculous Lymphadenitis in Children

    Journal of Pediatrics, Vol. 236, pp. 211-218.e2

  3. Prevalence of thrombotic complications in children with SARS-CoV-2

    Archives of Disease in Childhood, Vol. 106, Núm. 11, pp. 1129-1132

  4. Screening and Severity of Coronavirus Disease 2019 (COVID-19) in Children in Madrid, Spain

    JAMA Pediatrics

2020

  1. Epidemiological update on SARS-CoV-2 infection in Spain. Comments on the management of infection in pediatrics

    Anales de Pediatria, Vol. 92, Núm. 4, pp. 239-240

2019

  1. Impact of 13-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in children under 15 years old in Madrid, Spain, 2007 to 2016: The HERACLES clinical surveillance study

    Vaccine, Vol. 37, Núm. 16, pp. 2200-2207

2017

  1. Dexamethasone for Parapneumonic Pleural Effusion: A Randomized, Double-Blind, Clinical Trial

    Journal of Pediatrics, Vol. 185, pp. 117-123.e6

  2. Effect of the different 13-valent pneumococcal conjugate vaccination uptakes on the invasive pneumococcal disease in children: Analysis of a hospital-based and population-based surveillance study in Madrid, Spain, 2007-2015

    PLoS ONE, Vol. 12, Núm. 2

  3. Impact of 13-valent pneumococcal conjugate vaccine on pneumococcal meningitis in children

    Vaccine, Vol. 35, Núm. 35, pp. 4646-4651

2016

  1. Bacteremic Pneumonia before and after Withdrawal of 13-Valent Pneumococcal Conjugate Vaccine from a Public Vaccination Program in Spain: A Case-Control Study

    Journal of Pediatrics, Vol. 171, pp. 111-115.e3

  2. Complications of pneumococcal bacteremia after thirteen-valent conjugate vaccine withdrawal

    Pediatric Infectious Disease Journal, Vol. 35, Núm. 12, pp. 1281-1287

2013

  1. Expansion of serotype coverage in the universal pediatric vaccination calendar: Short-term effects on age- and serotype-dependent incidence of invasive pneumococcal clinical presentations in Madrid, Spain

    Clinical and Vaccine Immunology, Vol. 20, Núm. 10, pp. 1524-1530

  2. Impact of introduction of conjugate vaccines in the vaccination schedule on the incidence of pediatric invasive pneumococcal disease requiring hospitalization in Madrid 2007 to 2011

    Pediatric Infectious Disease Journal

2011

  1. Pandemic H1N1 influenza-associated hospitalizations in children in Madrid, Spain

    Influenza and other Respiratory Viruses, Vol. 5, Núm. 6

  2. Relationship between serotypes, age, and clinical presentation of invasive pneumococcal disease in Madrid, Spain, after introduction of the 7-valent pneumococcal conjugate vaccine into the vaccination calendar

    Clinical and Vaccine Immunology, Vol. 18, Núm. 1, pp. 89-94

2002

  1. Meningitis neumocócica en niños Españoles: Incidencia, serotipos y resistencia antibiótica. Estudio prospectivo multicéntrico

    Anales Espanoles de Pediatria, Vol. 57, Núm. 4, pp. 295-300